Main Content

Molecular Biomarker

COPD represents a major medical challenge due to its great heterogeneity with multiple comorbid traits and diseases.  Therefore, we carry out biologically-driven patient stratification based on polygenic risk scores to clinically define the relevance of different biomarkers (whole blood transcriptomics, extracellular vesicle surface proteomics, sputum microbiome) and to validate their correlation with the progression of the disease.

In our research project, we make use of existing clinical data to detect clinically relevant biomarkers and to validate them in a prospective, multi-center validation cohort. We take into account both technological feasibility as well as regulatory and commercial documentation and quality management standards to speed up technology transfer into translation and regulatory approval. The expertise we gain from these experiments aids in pre-preparatory work for the regulatory approval and clinical application that represent a major step towards a personalized medicine for COPD prevention and treatment.

People involved

Principle Investigators

Prof. Dr. Dominik Heider

Institute for Medical Informatics
Universität Münster

Prof. Dr. med. Bernd Schmeck

Institut für Lungenforschung
Philipps-Universität Marburg

Prof. Dr. med. Johnannes Schumacher

Institutfür Humangenetik
Philipps-Universität Marburg

Post-Doctoral Researchers

PD Dr. Wilhelm Goswin Bertrams

Institut für Lungenforschung
Philipps-Universität Marburg

Dr. Sandeep Grover

Institut für Humangenetik
Philipps-Universität Marburg

Dr. Katrin Laakmann

Institut für Lungenforschung
Philipps-Universität Marburg

Dr. Roman Martin

Data Science in der Biomedizin
Philipps-Universität Marburg

Dr. Hendrik Pott

Institut für Lungenforschung
Philipps-Universität Marburg

IVD Advisor

Dr. Joachim Wienbeck

Principal Software Engineer
Myriad Genetics